About: Lessons learned from a double-blind randomised placebo-controlled study with a iota-carrageenan nasal spray as medical device in children with acute symptoms of common cold

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Lessons learned from a double-blind randomised placebo-controlled study with a iota-carrageenan nasal spray as medical device in children with acute symptoms of common cold Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Lessons learned from a double-blind randomised placebo-controlled study with a iota-carrageenan nasal spray as medical device in children with acute symptoms of common cold
Creator	Diakos, Christopher Eickhoff, Philipp Fazekas, Tamas Fischmeister, Gustav Gadner, Helmut Lion, Thomas Pruckner, Nathalie Rauch, Margit Verdianz, Maria Vollnhofer, Georg Zoubek, Andreas
Source	Medline; PMC
abstract	BACKGROUND: Common cold is caused by a variety of respiratory viruses. The prevalence in children is high, and it potentially contributes to significant morbidity. Iota-carragenan, a polymer derived from red seaweed, has reduced viral load in nasal secretions and alleviated symptoms in adults with common cold. METHODS: We have assessed the antiviral and therapeutic activity of a nasal spray containing iota-carrageenan in children with acute symptoms of common cold. A cohort of 153 children between 1–18 years (mean age 5 years), displaying acute symptoms of common cold were randomly assigned to treatment with a nasal spray containing iota-carrageenan (0.12%) as verum or 0.9% sodium chloride solution as placebo for seven days. Symptoms of common cold were recorded and the viral load of respiratory viruses in nasal secretions was determined at two consecutive visits. RESULTS: The results of the present study showed no significant difference between the iota carrageenan and the placebo group on the mean of TSS between study days 2–7. Secondary endpoints, such as reduced time to clearance of disease (7.6 vs 9.4 days; p = 0.038), reduction of viral load (p = 0.026), and lower incidence of secondary infections with other respiratory viruses (p = 0.046) indicated beneficial effects of iota-carrageenan in this population. The treatment was safe and well tolerated, with less side effects observed in the verum group compared to placebo. CONCLUSION: In this study iota-carrageenan did not alleviate symptoms in children with acute symptoms of common cold, but significantly reduced viral load in nasal secretions that may have important implications for future studies. TRIAL REGISTRATION: ISRCTN52519535, http://www.controlled-trials.com/ISRCTN52519535/
has issue date	2012-09-05(xsd:dateTime)
bibo:doi	10.1186/1472-6882-12-147
bibo:pmid	22950667
has license	cc-by
sha1sum (hex)	ae79fbbd7e6130c0d5b451617260a7e63bda79e4
schema:url	https://doi.org/10.1186/1472-6882-12-147
resource representing a document's title	Lessons learned from a double-blind randomised placebo-controlled study with a iota-carrageenan nasal spray as medical device in children with acute symptoms of common cold
has PubMed Central identifier	PMC3575307
has PubMed identifier	22950667
schema:publication	BMC Complement Altern Med
resource representing a document's body	covid:ae79fbbd7e6130c0d5b451617260a7e63bda79e4#body_text
is schema:about of	named entity 'randomised' named entity 'PLACEBO-CONTROLLED STUDY' named entity 'ACUTE' covid:arg/ae79fbbd7e6130c0d5b451617260a7e63bda79e4 named entity 'MEDICAL DEVICE ' named entity 'PREVALENCE' named entity 'POLYMER' named entity 'CAUSED BY' named entity 'HIGH' named entity 'VIRAL LOAD' named entity 'REDUCED' named entity 'SIGNIFICANT' named entity 'MORBIDITY' named entity 'BACKGROUND' named entity 'RED' named entity 'VARIETY' named entity 'RESPIRATORY VIRUSES' named entity 'NASAL SECRETIONS' named entity 'DOUBLE' named entity 'IOTA-CARRAGEENAN' named entity 'SYMPTOMS' named entity 'NASAL SPRAY' named entity 'COMMON COLD' named entity 'CHILDREN' named entity 'SEAWEED' named entity 'COMMON COLD' named entity 'IOTA' named entity 'LEARNED' named entity 'ADULTS' named entity 'BLIND' named entity 'SYMPTOMS' named entity 'CHILDREN' named entity 'DERIVED' named entity 'red seaweed' named entity 'antibiotics' named entity 'common cold' named entity 'common cold' named entity 'high' named entity 'symptoms' named entity 'viral load' named entity 'common cold' named entity 'polymer' named entity 'double-blind' named entity 'antiviral' named entity 'wheezing' named entity 'virus' named entity 'Declaration of Helsinki' named entity 'human metapneumovirus' named entity 'primary endpoint' named entity 'symptom' named entity 'iota-carrageenan' named entity 'symptom' named entity 'OTC' named entity 'placebo' named entity 'adverse events' named entity 'placebo group' named entity 'iota-carrageenan' named entity 'double blind' named entity 'bacterial infections' named entity 'virus' named entity 'sore throat' named entity 'nasal secretions' named entity 'Carrageenan' named entity 'placebo-controlled' named entity 'primary endpoint' named entity 'pediatric' named entity 'antitussives' named entity 'symptom' named entity 'placebo' named entity 'coronaviruses' named entity 'antiviral activity'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software